The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn’s disease who failed prior infliximab therapy
Article first published online: 28 SEP 2010
© 2010 Blackwell Publishing Ltd
Alimentary Pharmacology & Therapeutics
Volume 32, Issue 10, pages 1228–1239, November 2010
How to Cite
Lichtiger, S., Binion, D. G., Wolf, D. C., Present, D. H., Bensimon, A. G., Wu, E., Yu, A. P., Cardoso, A. T., Chao, J., Mulani, P. M., Lomax, K. G. and Kent, J. D. (2010), The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn’s disease who failed prior infliximab therapy. Alimentary Pharmacology & Therapeutics, 32: 1228–1239. doi: 10.1111/j.1365-2036.2010.04466.x
- Issue published online: 19 OCT 2010
- Article first published online: 28 SEP 2010
- Publication data Submitted 29 March 2010 First decision 27 April 2010 Resubmitted 2 August 2010 Accepted 31 August 2010 EV Pub Online 28 September 2010
Figure S1. CHOICE study design. CHOICE, Crohn’s Disease WHO Failed Prior Infliximab to Collect Safety Data and Efficacy via Patient-Reported Outcome Measures; eow, every other week. Minimum study duration was 8 weeks. Data were analyzed through week 24.
Figure S2. Mean SIBDQ total scores by week of adalimumab therapy: all adalimumab and patients with and without fistula healing. Mean SIBDQ total scores showed statistically significant and rapid improvements that were maintained through week 24 (all adalimumab-treated patients, P < 0.05 vs. baseline). Greater scores indicate better HRQOL. HRQOL, health-related quality of life; SIBDQ, short inflammatory bowel disease questionnaire.
Figure S3. Mean WPAI scores by week of adalimumab therapy: patients with and without fistula healing. Decreases indicate less impairment. (a) Absenteeism. (b) Presenteeism. (c) TWPI. (d) TAI. TAI, total activity impairment; TWAI, total work productivity impairment; WPAI, Work Productivity and Activity Impairment Questionnaire.
Table S1. Infliximab history.
Table S2. Summary of infectious SAEs.
Table S3. Mean change from baseline in SIBDQ domain scores by visit: all adalimumab.
Table S4. Mean change from baseline in WPAI outcomes by visit.
|APT_4466_sm_fS1.TIF||16K||Supporting info item|
|APT_4466_sm_fS2.TIF||16K||Supporting info item|
|APT_4466_sm_fS3a.TIF||14K||Supporting info item|
|APT_4466_sm_fS3b.TIF||13K||Supporting info item|
|APT_4466_sm_fS3c.TIF||14K||Supporting info item|
|APT_4466_sm_fS3d.TIF||14K||Supporting info item|
|APT_4466_sm_tS1-4.doc||130K||Supporting info item|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.